ORIC Pharmaceuticals, Inc.
ORIC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.66 | 0.36 | -0.30 | 0.18 |
| FCF Yield | -20.23% | -18.28% | -33.06% | -10.84% |
| EV / EBITDA | -4.04 | -4.19 | -1.92 | -4.28 |
| Quality | ||||
| ROIC | -55.89% | -46.73% | -38.70% | -27.45% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.88 | 0.85 | 0.84 | 0.76 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -31.56% | -12.06% | -27.68% | -31.66% |
| Safety | ||||
| Net Debt / EBITDA | 0.39 | 0.12 | 0.73 | 2.87 |
| Interest Coverage | 0.00 | 0.00 | -34.69 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -510.41 | -333.88 | -498.76 | -767.44 |